These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
299 related articles for article (PubMed ID: 7954054)
1. Assessment of immunocytochemical and histochemical stainings in the distinction between reactive mesothelial cells and adenocarcinoma cells in body effusions. Chen CJ; Chang SC; Tseng HH Zhonghua Yi Xue Za Zhi (Taipei); 1994 Sep; 54(3):149-55. PubMed ID: 7954054 [TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913 [TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338 [TBL] [Abstract][Full Text] [Related]
4. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry. Su XY; Li GD; Liu WP; Xie B; Jiang YH Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004 [TBL] [Abstract][Full Text] [Related]
5. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions. Friedman MT; Gentile P; Tarectecan A; Fuchs A Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609 [TBL] [Abstract][Full Text] [Related]
6. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1. Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030 [TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of mesothelial cells and carcinoma cells with monoclonal antibodies to cytokeratins, vimentin, CEA and EMA improves the cytodiagnosis of serous effusions. Daste G; Serre G; Mauduyt MA; Vincent C; Caveriviere P; Soleilhavoup JP Cytopathology; 1991; 2(1):19-28. PubMed ID: 1715202 [TBL] [Abstract][Full Text] [Related]
8. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1]. Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046 [TBL] [Abstract][Full Text] [Related]
9. Distinction between cells in serous effusions using a panel of antibodies. Lauritzen AF Virchows Arch A Pathol Anat Histopathol; 1987; 411(3):299-304. PubMed ID: 2441518 [TBL] [Abstract][Full Text] [Related]
10. Use of a panel of markers in the differential diagnosis of adenocarcinoma and reactive mesothelial cells in fluid cytology. Ko EC; Jhala NC; Shultz JJ; Chhieng DC Am J Clin Pathol; 2001 Nov; 116(5):709-15. PubMed ID: 11710688 [TBL] [Abstract][Full Text] [Related]
11. [The immunocytochemical study of pleural effusion and ascites using Ber-EP-4 antibodies]. Spehn J; Iwanetz S; Schmitz-Huebner U Dtsch Med Wochenschr; 1995 Sep; 120(36):1197-200. PubMed ID: 7671771 [TBL] [Abstract][Full Text] [Related]
13. [Significance of combining detection of E-cadherin, carcinoembryonic antigen, and calretinin in cytological differential diagnosis of serous effusion]. Su XY; Li GD; Liu HB; Jiang LL Ai Zheng; 2004 Oct; 23(10):1185-9. PubMed ID: 15473932 [TBL] [Abstract][Full Text] [Related]
14. Markers for metastatic adenocarcinoma in serous effusion specimens. Shield PW; Callan JJ; Devine PL Diagn Cytopathol; 1994; 11(3):237-45. PubMed ID: 7532566 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic usefulness of EMA, IMP3, and GLUT-1 for the immunocytochemical distinction of malignant cells from reactive mesothelial cells in effusion cytology using cytospin preparations. Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T Diagn Cytopathol; 2011 Jun; 39(6):395-401. PubMed ID: 21574259 [TBL] [Abstract][Full Text] [Related]
16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology. Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157 [TBL] [Abstract][Full Text] [Related]
17. [Use of immunohistochemistry in clinical cytology]. Weintraub D; Weintraub J; Vassilakos P Ann Pathol; 1987; 7(1):25-30. PubMed ID: 3304314 [TBL] [Abstract][Full Text] [Related]
18. Application of Leu M5 (CD 11c) antibody in the cytodiagnosis of body fluids: preliminary results. Berena J; Sun NC J Clin Lab Anal; 1993; 7(1):19-25. PubMed ID: 8093902 [TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids. Afify A; Zhou H; Howell L; Paulino AF Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901 [TBL] [Abstract][Full Text] [Related]
20. New diagnostic technique for rapid fluorescence immunocytochemical staining of adenocarcinoma and mesothelial cells using liquid-based cytology. Morimoto A; Ito A; Hashimoto K; Nakano A; Nagasaka T; Yokoi T Acta Cytol; 2014; 58(5):461-8. PubMed ID: 25358455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]